Godavari Bioref. Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹549 Cr +27.4% YoYSee revenue, profit and what management said. You are viewing Q3 FY26.
GB

Godavari Bioref.

Q3 FY26Diversified FMCG

Godavari Biorefineries Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹460Cr
+2.9% YoY
+6.7% QoQ
Net profit
₹8Cr
+33.3% YoY
Turned profitable QoQ
Margin
9%
+1 pp YoY
+10.8 pp QoQ
Price₹241
Market cap₹1.3K Cr
P/E43.6

The short version

Godavari Biorefineries expects robust growth through capacity expansions, especially in grain/maize-based ethanol distilleries. Godavari Biorefineries aims to achieve a 3x EBITDA growth by FY29, targeting INR 3000 crores topline with 10-11% EBITDA margin (Page 13).

From Godavari Bioref.'s Q3 FY26 earnings-call transcript · updated 25 Aug 2026.

Revenue & Sales Performance

  • Godavari Biorefineries expects robust growth through capacity expansions, especially in grain/maize-based ethanol distilleries.
  • The company targets a significant increase in revenue, aiming for close to INR 3,000 crores topline by 2029 with 10-11% EBITDA margin.
  • Expansion of bio-based chemicals, including specialty chemicals and bio-based monomers, is a key driver for high-margin growth.
  • Increasing ethanol blending mandates (E20 achieved 5 years ahead of schedule) and potential introduction of flex fuel vehicles will boost ethanol demand.
  • Continuous innovation and co-creation with customers to develop green transition products underpin growth.

2 more points from Godavari Bioref.'s call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Godavari Bioref. said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Godavari Biorefineries is investing in capacity expansion, notably:
  • Adding a grain-based (maize) ethanol distillery facility, with commissioning expected next quarter due to some equipment delays.
  • Continuing investments in bio-based specialty chemicals capacity through debottlenecking and expansions.
  • Total planned capex is estimated at INR 325 crores by FY29, with approximately 75% allocated to bio-based chemicals and 25% to ethanol.
  • Strategic investments include:
  • Licensing deal with Catalyxx for bio-based butanol production.
  • Collaboration with Synthomer to commercialize bio-based butyl acrylate.
  • Pilot plant development for dimethyl ether (DME) technology in partnership with the Institute of Chemical Technology.

2 more points from Godavari Bioref.'s call on capex

Create a free account to keep reading this call

Fundraising & Capital Structure

See what Godavari Bioref. said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • The company has received binding supply obligations for ethanol volumes through OMC tenders for the ethanol supply year.
  • Operational and financial preparations are underway to service these mandated volumes despite margin pressures from rising cane costs.
  • The grain-based ethanol facility commissioning is delayed but expected by next quarter, which will support their capacity to meet orders.

2 more points from Godavari Bioref.'s call on order book

Create a free account to keep reading this call

Godavari Bioref. — Quarterly revenue & net profit

Revenue Net profit Net loss
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Godavari Bioref. Q3 FY26 results — key figures

Godavari Bioref. Q3 FY26 reported results vs Q3 FY25, ₹ crore
₹ CrQ3 FY26Q3 FY25YoYQ2 FY26QoQ
Revenue460447+2.9%431+6.7%
Operating profit (EBITDA)4336+19.4%-8—
Operating margin9%8%+1 pp-1.8%+10.8 pp
Profit before tax138+62.5%-57—
Net profit (PAT)86+33.3%-42—
EPS (₹)1.611.13+42.5%-8.13—

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹549 Cr, net loss ₹15 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Godavari Bioref. and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Godavari Bioref. Q3 FY26 results?

Godavari Biorefineries expects robust growth through capacity expansions, especially in grain/maize-based ethanol distilleries. Godavari Biorefineries aims to achieve a 3x EBITDA growth by FY29, targeting INR 3000 crores topline with 10-11% EBITDA margin (Page 13).

What is Godavari Bioref. share price analysis?

Godavari Bioref. currently shows a neutral. The stock trades at a P/E of 43.6 with a market cap of ₹1,265 Cr. Investors should review the full earnings analysis for detailed insights.

Is Godavari Bioref. planning capital expenditure?

Godavari Biorefineries is investing in capacity expansion, notably: - Adding a grain-based (maize) ethanol distillery facility, with commissioning expected next quarter due to some equipment delays.

Keep Godavari Bioref. on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.